Patient BMI plays a prognostic role when using atezolizumab + bevacizumab vs lenvatinib for patients with advanced #HCC in the first line. Investigators noted that no prognostic effect was observed in patients treated with lenvatinib.

targetedonc.com/view/bmi-affec…

Learn more about our 2024 Oncology Icon, Sanjay Juneja, MD, in this interview! Sanjay Juneja, MD Mary Bird Perkins

targetedonc.com/view/education…

WATCH: Prithviraj Bose, MD, on Factors Considered for Initial Therapy in #Myelofibrosis . #MPNSM | MD Anderson Cancer Center

targetedonc.com/view/factors-c…

What are the most significant developments in targeted therapies and liquid biopsies in recent years? Dr. Bartlett of AHN discusses updates in genomic testing for cancer patients with Targeted Oncology: bit.ly/3TUymFx #ctDNA #LiquidBiopsy #CancerResearch #CancerPatient

WATCH: Anne P. O'Dea, MD, presents the case of a 49-year-old woman with HR+/HER2- metastatic breast cancer and offers initial impressions on the patient’s risk and prognosis. #BCSM | The University of Kansas Health System

targetedonc.com/view/patient-p…

Prithviraj Bose, MD, of MD Anderson Cancer Center discusses his initial impressions of the case and how it compares to typical #myelofibrosis cases seen in his practice.

targetedonc.com/view/initial-i…

Cellular therapies have emerged as effective treatments for hematologic malignancies, yet progress in applying them to #AML lags behind. However, identifying new targets is driving innovation. Naval Daver, M.D. Musa Yilmaz, MD MD Anderson Cancer Center St. Jude Research

targetedonc.com/view/cell-ther…

An overview of the iNTEGRATE and ROCKstar trials by Yi-Bin Chen, MD, where he discusses their significance in the current treatment paradigm for #GVHD . Mass General Cancer Center

targetedonc.com/view/updates-o…

WATCH: Ira Zackon, MD, discusses the background of a real-world study which sought to identify some of the racial and socioeconomic disparities seen in patients with #CLL . #LEUSM | New York Oncology Hematology The US Oncology Network

targetedonc.com/view/real-worl…

In an interview with Targeted Oncology for Head & Neck Cancer Awareness Month, Noel Laudi, MD, MRCP, discussed the link between HPV infection and head and neck cancers. #hancsm | Allina Health

targetedonc.com/view/exploring…

The approval of belzutifan & other newer data for treating recurrent #RCC has allowed subsequent therapies to advance beyond the reuse of frontline options with impacts on duration of response and quality of life. #KCSM | MD Anderson Cancer Center MedStar Health

targetedonc.com/view/advances-…

WATCH: Yi-Bin Chen, MD, on findings from the REACH-3 Trial, highlighting the superior best overall response rate of 75% in the experimental arm vs 60% in the best-available therapy arm. Mass General Cancer Center

targetedonc.com/view/lessons-l…

In this interview, Warren Fingrut of MD Anderson Cancer Center discussed a study looking at HLA antibody burden among patients with blood cancers, particularly women who have carried multiple pregnancies.

targetedonc.com/view/investiga…

No differences in efficacy and safety were seen in a study cohort of 1325 patients undergoing frontline treatment with lenvatinib for unresectable #HCC .

targetedonc.com/view/lenvatini…

Tina Cascone, MD, PhD, discusses the CheckMate-77T trial of perioperative regimen of neoadjuvant nivolumab + chemotherapy followed by surgery and adjuvant nivolumab for the treatment of patients with stage IIA to IIIB #NSCLC .

targetedonc.com/view/behind-th…

In this Targeted Oncology interview, Debra Patt shares how technology can help healthcare providers work smarter, reduce administrative burdens, and improve work/life balance. #WorkLifeBalance #Burnout #AI #Technology
targetedonc.com/view/technolog…

Nogapendekin alfa led to overall survival improvements in patients with second- and third-line #NSCLC who progressed after checkpoint inhibitors + chemo, according to data from the phase 2b QUILT-3.055 study. #LCSM

targetedonc.com/view/nogapende…

#GISeries : Here we🗣️about the U.S. FDA approval of #Fruquintinib from #FRESCO2 & how it fits in our Rx paradigm w/Arvind Dasari, MD, MS

Full Int:
- targetedonc.com/pivotal-practi…
- oncbrothers.com/JC-FRESCO2
- Also on the “Oncology Brothers” podcast

#OncTwitter #MedTwitter Targeted Oncology #crcsm

Ben Jones identified the key challenges community oncologists are facing due to legislative changes in cancer care policy. The US Oncology Network

targetedonc.com/view/legislati…

Leyla Shune, MD, discussed the emergence of talquetamab-tgvs for patients with relapsed/refractory multiple myeloma. #MMSM | Leyla Shune MD KU Cancer Center

targetedonc.com/view/gprc5d-ta…